U. Minnesota Drug Patents
Sen. Boschwitz (R-Minn.) introduced legislation Feb. 7 to extend the patents of two cardiac drugs developed by the University of Minnesota -- the injectable anti-arrhythmic bretylium tosylate (American Critical Care's Bretylol) and the oral antihypertensive bethanidine sulfate (Robins' Tenathan). The bill (S 456) would provide five-year extensions for bretylium and bethanidine, whose patents expire in 1986 and 1987, respectively. Both drugs were approved in 1981. Boschwitz said industry or university funding of comparative studies is "impracticable" unless the patents are extended. He added that Senate Judiciary/Patents Subcmte. Chairman Mathias (R-Md.) has agreed to hold hearings on the bill
You may also be interested in...
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.